Related Experiment Video
Updated: Aug 23, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Saquinavir/low-dose ritonavir: its use in HIV infection
Margaret Johnson1, Barry Peters
1Infection and Immunity Services, Royal Free Hospital, Pons Street, London NW3 2QG, UK. ma@johnson.u-net.com
Abstract:
Exposure to saquinavir can be increased considerably by pharmacokinetic enhancement with ritonavir, without having a substantial impact on tolerability. Clinical trials indicate that both once-daily and twice-daily saquinavir/ritonavir treatment regimens, generally at dosages of 1,600 mg/100 mg once daily and 1,000 mg/100 mg twice daily, provide potent and sustained viral suppression and are well tolerated. In addition, data suggest that "double-boosting" strategies, including the combination of saquinavir with lopinavir/ritonavir, provide valuable treatment options in the salvage setting.
Related Concept Videos
Retrovirus Life Cycles
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Subviral Agents
Respiratory Syncytial Virus Disease
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors

